The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats

Neuropharmacology

Volumn 54, Issue 2, 2008, Pages 438-444

  Shoaib, Mohammed ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Addiction; Endocannabinoids; Nicotine; Reinstatement; Self administration

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; NICOTINE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SELF ADMINISTRATION; DRUG SPECIFICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOKING CESSATION; TOBACCO DEPENDENCE;

ANIMALS; CANNABINOIDS; CONDITIONING, OPERANT; CUES; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD; MALE; NICOTINE; NICOTINIC AGONISTS; PIPERIDINES; PYRAZOLES; RATS; RECURRENCE; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; TOBACCO USE DISORDER;

EID: 38149049092     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.10.011     Document Type: Article

References (33)

1. Anthenelli R.M. The endocannabinoid system as a therapeutic target for smoking cessation. Meeting of the Society for Research on Nicotine and Tobacco (2004), Tübingen
2. Arnone M., Maruani J., Chaperon F., Thiebot M.H., Poncelet M., Soubrie P., and Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132 (1997) 104-106
3. Burns L.H., Everitt B.J., Kelley A.E., and Robbins T.W. Glutamate-dopamine interactions in the ventral striatum: role in locomotor activity and responding with conditioned reinforcement. Psychopharmacology 115 (1994) 516-528
4. Caggiula A.R., Donny E.C., Chaudhri N., Perkins K.A., Evans-Martin F.F., and Sved A.F. Importance of nonpharmacological factors in nicotine self-administration. Physiology and Behavior 77 (2002) 683-687
5. Chambers A.P., Sharkey K.A., and Koopmans H.S. Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. Physiology and Behavior 82 (2004) 863-869
6. Chaudhri N., Caggiula A.R., Donny E.C., Palmatier M.I., Liu X., and Sved A.F. Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology 184 (2006) 353-366
7. Chiamulera C., Borgo C., Falchetto S., Valerio E., and Tessari M. Nicotine reinstatement of nicotine self-administration after long-term extinction. Psychopharmacology 127 (1996) 102-107
8. Cohen C., Perrault G., Voltz C., Steinberg R., and Soubrie P. SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behavioural Pharmacology 13 (2002) 451-463
9. Cohen C., Kodas E., and Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacology. Biochemistry and Behavior 81 (2005) 387-395
10. Cohen C., Perrault G., Griebel G., and Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 30 (2005) 145-155
11. Columbo G., Agabio R., Diaz G., Lobina C., Reali R., and Gessa G. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sciences 63 (1998) 113-117
12. De Vries T.J., and Schoffelmeer A.N. Cannabinoid CB1 receptors control conditioned drug seeking. Trends in Pharmacological Sciences 26 (2005) 420-426
13. De Vries T.J., de Vries W., Janssen M.C., and Schoffelmeer A.N. Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behavioural Brain Research 161 (2005) 164-168
14. DiMarzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake (see comment). Nature 410 (2001) 822-825
15. Duarte C., Alonso R., Bichet N., Cohen C., Soubrie P., and Thiebot M.H. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior. Neuropsychopharmacology 29 (2004) 911-920
16. Forget B., Hamon M., and Thiebot M.H. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology 181 (2005) 722-734
17. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. European Journal of Pharmacology 307 (1996) 331-338
18. Gatley S.J., Lan R., Pyatt B., Gifford A.N., Volkow N.D., and Makriyannis A. Binding of the non-classical cannabinoid CP 55, 940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sciences 61 (1997) L-7
19. George T.P., and O'Malley S.S. Current pharmacological treatments for nicotine dependence. Trends in Pharmacological Sciences 25 (2004) 42-48
20. Gonzales S., Cascio M., Fernandez-Ruiz J., DiMarzo V., and Ramos J. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Research 954 (2002) 73-81
21. Kirkham T.C. Endocannabinoids in the regulation of appetite and body weight. Behavioural Pharmacology 16 (2005) 297-313
22. Le Foll B., and Goldberg S.R. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. NeuroReport 15 (2004) 2139-2143
23. McLaughlin P.J., Winston K., Swezey L., Wisniecki A., Aberman J., Tardif D.J., Betz A.J., Ishiwari K., Makriyannis A., and Salamone J.D. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behavioural Pharmacology 14 (2003) 583-588
24. Olausson P., Jentsch J.D., and Taylor J.R. Nicotine enhances responding with conditioned reinforcement. Psychopharmacology 171 (2004) 173-178
25. Patel S., and Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. Journal of Pharmacology and Experimental Therapeutics 318 (2006) 304-311
26. Robbins T.W. Relationship between reward-enhancing and stereotypical effects of psychomotor stimulant drugs. Nature 264 (1976) 57-59
27. Shaham Y., Adamson L.K., Grocki S., and Corrigall W.A. Reinstatement and spontaneous recovery of nicotine seeking in rats. Psychopharmacology 130 (1997) 396-403
28. Shoaib M. Effects of isoarecolone, a nicotinic receptor agonist in rodent models of nicotine dependence. Psychopharmacology 188 (2006) 252-257
29. Shoaib M., Schindler C.W., and Goldberg S.R. Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology 129 (1997) 35-43
30. Stolerman I.P., and Jarvis M.J. The scientific case that nicotine is addictive. Psychopharmacology 117 (1995) 2-10
31. Warner C., and Shoaib M. How does bupropion work as a smoking cessation aid?. Addiction Biology 10 (2005) 219-231
32. Xi Z.X., Gilbert J.G., Peng X.Q., Pak A.C., Li X., and Gardner E.L. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. Journal of Neuroscience 26 (2006) 8531-8536
33. Zaniewska M., McCreary A.C., Przegaliski E., and Filip M. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. European Journal of Pharmacology 540 (2006) 96-106